(Q84512650)

English

Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group

scientific article published on 05 July 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21733566%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21733566%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

based on heuristic

inferred from title

11

object named as

I Vergote

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21733566%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

author name string

K Baumann

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21733566%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

J Pfisterer

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21733566%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

P Wimberger

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21733566%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

N Burchardi

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21733566%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

C Kurzeder

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21733566%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

A du Bois

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21733566%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

S Loibl

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21733566%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

J Sehouli

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21733566%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

J Huober

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21733566%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

B Schmalfeldt

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21733566%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

H J Lück

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21733566%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

U Wagner

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21733566%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

publication date

5 July 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21733566%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21733566%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

123

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21733566%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21733566%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

27-32

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21733566%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.004

7 January 2021

Epithelial ovarian cancer: a review of current management

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.004

7 January 2021

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.004

7 January 2021

Compliance to consensus recommendations, surgeon's experience, and introduction of a quality assurance and management program: influence on therapy of early-stage ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.004

7 January 2021

Update on Gynecologic Oncology Group (GOG) trials in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.004

7 January 2021

First-line therapy for ovarian carcinoma: what's next?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.004

7 January 2021

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.004

7 January 2021

Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6)

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.004

7 January 2021

Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.004

7 January 2021

Standard treatment in advanced ovarian cancer in 2005: the state of the art.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.004

7 January 2021

Treatment goals in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.004

7 January 2021

From the archives of the AFIP: radiologic staging of ovarian carcinoma with pathologic correlation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.004

7 January 2021

Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.004

7 January 2021

Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.004

7 January 2021

EpCAM (CD326) finding its role in cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.004

7 January 2021

Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.004

7 January 2021

Frequent EpCam protein expression in human carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.004

7 January 2021

Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.004

7 January 2021

Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.004

7 January 2021

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.004

7 January 2021

Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3).

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.004

7 January 2021

The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.004

7 January 2021

Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.004

7 January 2021

The evolving role of catumaxomab in gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.004

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.004

7 January 2021

Use of CA-125 to Assess Response to New Agents in Ovarian Cancer Trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.004

7 January 2021

Ovarian cancer: strategies for overcoming resistance to chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.004

7 January 2021

The impact of T-cell immunity on ovarian cancer outcomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.004

7 January 2021

Suppressive activity rather than frequency of FoxP3(+) regulatory T cells is essential for CA-125-specific T-cell activation after abagovomab treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.004

7 January 2021

Efficacy of catumaxomab in tumor spheroid killing is mediated by its trifunctional mode of action

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.004

7 January 2021

Human antiglobulin response to foreign antibodies: therapeutic benefit?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.004

7 January 2021

Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.004

7 January 2021

Intraperitoneal bispecific antibody (HEA125xOKT3) therapy inhibits malignant ascites production in advanced ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.004

7 January 2021

Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.004

7 January 2021

Identifiers

10.1016/J.YGYNO.2011.06.004

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21733566%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21733566%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q84512650&oldid=1522487921"